Neuropeptide y and peptide YY: Important regulators of energy metabolism

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 18, Issue 1, 2011, Pages 56-60

  Nguyen, Amy D ^a   Herzog, Herbert ^a,b   Sainsbury, Amanda ^a,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b Faculty of Medicine   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Gut; hypothalamus; neuropeptide Y; obesity; peptide YY

Indexed keywords

ANOREXIGENIC AGENT; APPETITE STIMULANT; CANNABINOID; NEUROPEPTIDE Y; OXYNTOMODULIN; PEPTIDE YY; PYY3 36; UNCLASSIFIED DRUG;

AEROBIC EXERCISE; ARCUATE FASCICULUS; ARTICLE; CARDIOVASCULAR DISEASE; ENERGY METABOLISM; FOOD INTAKE; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; LIPID DIET; METABOLIC DISORDER; NAUSEA; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; RISK REDUCTION; STOMACH EMPTYING; WEIGHT REDUCTION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRAIN; ENERGY METABOLISM; HUMANS; NEUROPEPTIDE Y; PEPTIDE YY;

EID: 78650805826     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283422f0a     Document Type: Article

References (64)

1. Stanley BG, Anderson KC, Grayson MH, et al. Repeated hypothalamic stimulation with neuropeptide Y increases daily carbohydrate and fat intake and body weight gain in female rats. Physiol Behav 1989; 46:173-177.
2. Kotz CM, Briggs JE, Grace MK, et al. Divergence of the feeding and thermogenic pathways influenced by NPY in the hypothalamic PVN of the rat. Am J Physiol 1998; 275 (2 Pt 2):R471-R477.
3. Lin EJ, Sainsbury A, Lee NJ, et al. Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. Endocrinology 2006; 147:5094-5101.
4. Raposinho PD, Pierroz DD, Broqua P, et al. Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol Cell Endocrinol 2001; 185:195-204.
5. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418:650-654.
6. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349:941-948.
7. Playford RJ, Domin J, Beacham J, et al. Preliminary report: role of peptide YY in defence against diarrhoea. Lancet 1990; 335:1555-1557.
8. Cox HM, Tough IR. Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa. Br J Pharmacol 2002; 135:1505-1512.
9. Morimoto R, Satoh F, Murakami O, et al. Expression of peptide YY in human brain and pituitary tissues. Nutrition 2008; 24:878-884.
10. Jesudason DR, Monteiro MP, McGowan BM, et al. Low-dose pancreatic polypeptide inhibits food intake in man. Br J Nutr 2007; 97:426-429.
11. Lin S, Shi YC, Yulyaningsih E, et al. Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice. PLoS One 2009; 4:e8488.
12. Lin S, Boey D, Herzog H. NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides 2004; 38:189-200.
13. Ellacott KL, Cone RD. The central melanocortin system and the integration of short- and long-term regulators of energy homeostasis. Recent Prog Horm Res 2004; 59:395-408.
14. Ollmann MM, Wilson BD, Yang YK, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997; 278:135-138.
15. MacLean PS, Higgins JA, Johnson GC, et al. Metabolic adjustments with the development, treatment, and recurrence of obesity in obesity-prone rats. Am J Physiol Regul Integr Comp Physiol 2004; 287:R288-R297.
16. Klem ML, Wing RR, Lang W, et al. Does weight loss maintenance become easier over time? Obes Res 2000; 8:438-444.
17. Yu Y, Deng C, Huang XF. Obese reversal by a chronic energy restricted diet leaves an increased Arc NPY/AgRP, but no alteration in POMC/CART, mRNA expression in diet-induced obese mice. Behav Brain Res 2009; 205:50-56.
18. Yang L, Scott KA, Hyun J, et al. Role of dorsomedial hypothalamic neuropeptide Y in modulating food intake and energy balance. J Neurosci 2009; 29:179-190.
19. Dhillon H, Zigman JM, Ye C, et al. Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron 2006; 49:191-203.
20. Majdic G, Young M, Gomez-Sanchez E, et al. Knockout mice lacking steroidogenic factor 1 are a novel genetic model of hypothalamic obesity. Endocrinology 2002; 143:607-614.
21. King BM. The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight. Physiol Behav 2006; 87:221-244.
22. Jolicoeur FB, Bouali SM, Fournier A, et al. Mapping of hypothalamic sites involved in the effects of NPY on body temperature and food intake. Brain Res Bull 1995; 36:125-129.
23. Chee MJ, Myers MG Jr, Price CJ, et al. Neuropeptide Y suppresses anorexigenic output from the ventromedial nucleus of the hypothalamus. J Neurosci 2010; 30:3380-3390.
24. Shi YC, Lin S, Wong IP, et al. NPY neuron-specific Y2 receptors regulate adipose tissue and trabecular bone but not cortical bone homeostasis in mice. PLoS One 2010; 5:e11361.
25. Broberger C, Landry M, Wong H, et al. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortinand neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 1997; 66:393-408.
26. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112:423-431.
27. Herling AW, Kilp S, Juretschke HP, et al. Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant. Int J Obes (Lond) 2008; 32:1363-1372.
28. Liu YL, Connoley IP, Wilson CA, et al. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005; 29:183-187.
29. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to dietinduced obesity. J Clin Invest 2005; 115:1298-1305.
30. Gary-Bobo M, Elachouri G, Scatton B, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006; 69:471-478.
31. Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118:3160-3169.
32. Baldock PA, Allison SJ, Lundberg P, et al. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem 2007; 282:19092-19102.
33. Allison SJ, Baldock PA, Enriquez RF, et al. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis. J Bone Miner Res 2009; 24:294-304.
34. Lundberg P, Allison SJ, Lee NJ, et al. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem 2007; 282:19082-19091.
35. Baldock PA, Sainsbury A, Couzens M, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002; 109:915-921.
36. Zhang L, Lee NJ, Nguyen AD, et al. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Diabetes Obes Metab 2010; 12:591-603.
37. Broberger C, Landry M, Wong H, et al. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortinand neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 1997; 66:393-408.
38. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112:423-431.
39. Herling AW, Kilp S, Juretschke HP, et al. Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant. Int J Obes (Lond) 2008; 32:1363-1372.
40. Liu YL, Connoley IP, Wilson CA, et al. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005; 29:183-187.
41. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to dietinduced obesity. J Clin Invest 2005; 115:1298-1305.
42. Gary-Bobo M, Elachouri G, Scatton B, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006; 69:471-478.
43. Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118:3160-3169.
44. Baldock PA, Allison SJ, Lundberg P, et al. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem 2007; 282:19092-19102.
45. Allison SJ, Baldock PA, Enriquez RF, et al. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis. J Bone Miner Res 2009; 24:294-304.
46. Lundberg P, Allison SJ, Lee NJ, et al. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem 2007; 282:19082-19091.
47. Baldock PA, Sainsbury A, Couzens M, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002; 109:915-921.
48. Zhang L, Lee NJ, Nguyen AD, et al. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Diabetes Obes Metab 2010; 12:591-603.
49. Chu ZL, Carroll C, Alfonso J, et al. A role for intestinal endocrine cellexpressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 2008; 149:2038-2047.
50. Cox HM, Tough IR, Woolston AM, et al. Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses. Cell Metab 2010; 11:532-542.
51. Witte AB, Gryback P, Holst JJ, et al. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Regul Pept 2009; 158:57-62.
52. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 2005; 146:879-888.
53. Moran TH, Smedh U, Kinzig KP, et al. Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 2005; 288:R384-R388.
54. Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005; 129:1430-1436.
55. Gutzwiller JP, Degen L, Matzinger D, et al. Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. Am J Physiol Regul Integr Comp Physiol 2004; 287:R562-R567.
56. Neary NM, Small CJ, Druce MR, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146: 5120-5127.
57. Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54:2390-2395.
58. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin EndocrinolMetab 2003; 88:4696-4701.
59. Le Roux CW, Borg CM, Murphy KG, et al. Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake. Ann Clin Biochem 2008; 45 (Pt 1):93-95.
60. Le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246:780-785.
61. Field BC, Wren AM, Peters V, et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59:1635-1639.
62. Kelley GA, Kelley KS. Efficacy of aerobic exercise on coronary heart disease risk factors. Prev Cardiol 2008; 11:71-75.
63. Jones TE, Basilio JL, Brophy PM, et al. Long-term exercise training in overweight adolescents improves plasma peptide YY and resistin. Obesity (Silver Spring) 2009; 17:1189-1195.
64. Ueda SY, Yoshikawa T, Katsura Y, et al. Comparable effects of moderate intensity exercise on changes in anorectic gut hormone levels and energy intake to high intensity exercise. J Endocrinol 2009; 203:357-364.